Studies on flu like H1NI led to info on homoeo meds: govt

Image
Press Trust of India New Delhi
Last Updated : Mar 13 2015 | 5:22 PM IST
Studies on influenza like the H1N1 during swine flu pandemic in 2009 has resulted in identification of specific homoeopathic medicines, Lok Sabha was informed today.
Union Minister of State for AYUSH Shripad Yesso Naik said this in a written reply, in response to a question in Parliament.
"Collaborative studies on influenza like illness (ILI) and H1N1, conducted by Central Council for Research in Homoeopathy (CCRH) during pandemic of H1N1 in 2009 resulted in identification of specific homoeopathic medicines.
"A multi-centric randomised placebo controlled trial with individualised homoeopathic treatment in ILI has also been conducted," Naik said.
He said a preliminary study conducted by Central Council for Research in Unani Medicine (CCRUM) in collaboration with Jamia Hamdard in New Delhi on Pulmonary Tuberculosis (Diq-e-Revi) have shown significant effects of Unani drugs as immunomodulator leading to better and early resolution of lesions.
Immunomodulators weaken or modulate the activity of the immune system while a lesions is a region in an organ or tissue which has suffered damage through injury.
Naik also said Homoeopathy has a positive role to decrease viral load in HIV-positive patients, increase CD4 count and improve the quality of life.
He said that various research councils have undertaken large number of projects on various diseases and majority of these projects are mostly multi-centric covering more than one state.
"Studies in respect of above projects have been completed. The results have also shown that Homoeopathy has a positive role to decrease viral load in HIV-positive patients, increase CD4 count and improve the quality of life," Naik said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 13 2015 | 5:22 PM IST

Next Story